Sandoz has launched its AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD in Portugal and Ireland, the company said. AirFluSal is now available in twelve European countries, South Korea, and Mexico.
The Portuguese Health Authority approved the DPI in October 2014, and Ireland approved the inhaler in November, 2014.
Sandoz Head of the Global Respiratory Franchise Jan-Torsten Tews commented, “We are pleased to reach another milestone in our journey to make AirFluSal available to patients suffering from asthma and COPD. This is an affordable and award winning new therapeutic option, developed in close collaboration with patients.”
Read the Sandoz press release.
